Novel inhibitor of the in vivo aggregation of

Novel NR4A nuclear receptor modulator

Novel NR4A nuclear receptor modulator

Selective neurotensin antagonist

Novel Unc-51-Like Kinase 1 (ULK1)

Novel partial agonist of PPARgamma

Novel NR4A nuclear receptor modulator

Potent inhibitor of both JNK3 and p38

Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3)

Novel renin inhibitor

The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents

Novel Selective TBK1/IKK dual inhibitor with anticancer potency

Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR)

Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK)

Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist

Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons.

Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding

Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv)

Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice